Literature DB >> 16635485

Zeta-sarcoglycan is a functional homologue of gamma-sarcoglycan in the formation of the sarcoglycan complex.

Kazuo Shiga1, Hiroki Yoshioka, Teruhiko Matsumiya, Ichiro Kimura, Shin'ichi Takeda, Michihiro Imamura.   

Abstract

The sarcoglycans (SGs), transmembrane components of the dystrophin-associated glycoprotein complex, are stable and functional only when they assemble into a tetrameric complex in muscle cells. A defect in any one of the four SG members disrupts the entire SG complex (SGC) and causes limb-girdle muscular dystrophy. zeta-SG has been recently found as a transmembrane protein homologous to gamma-SG and delta-SG. To characterize zeta-SG in complex formation, we co-transfected expression vectors encoding all six SGs (alpha-, beta-, gamma-, delta-, epsilon- and zeta-SG) and dystroglycan into Chinese hamster ovary cells. Immunoprecipitation analysis showed that zeta-SG or gamma-SG formed a SGC with beta-SG and delta-SG plus alpha-SG or epsilon-SG, revealing that zeta-SG can form two types of SGCs (alpha-beta-zeta-delta or epsilon-beta-zeta-delta). This result indicates the functional resemblance of zeta-SG to gamma-SG rather than delta-SG, although phylogenetic analysis suggests that zeta-SG is evolutionally closer to delta-SG than to gamma-SG. Reverse transcription (RT)-PCR showed that the expression pattern of the transcript was almost the reciprocal of that of gamma-SG in various mouse tissues and that the zeta-SG transcript was especially abundant in the brain, suggesting that zeta-SG might play a particular role in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635485     DOI: 10.1016/j.yexcr.2006.03.011

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models.

Authors:  Fumiaki Yokoi; Mai T Dang; Tong Zhou; Yuqing Li
Journal:  Hum Mol Genet       Date:  2011-11-11       Impact factor: 6.150

2.  A new evidence for the maintenance of the sarcoglycan complex in muscle sarcolemma in spite of the primary absence of delta-SG protein.

Authors:  Telma L F Gouveia; Patrícia M Kossugue; Julia F Paim; Mayana Zatz; Louise V B Anderson; Vincenzo Nigro; Mariz Vainzof
Journal:  J Mol Med (Berl)       Date:  2007-01-30       Impact factor: 4.599

Review 3.  Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects.

Authors:  George R Uhl; Tomas Drgon; Catherine Johnson; Chuan-Yun Li; Carlo Contoreggi; Judith Hess; Daniel Naiman; Qing-Rong Liu
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

4.  Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan.

Authors:  Stefano Gastaldello; Simona D'Angelo; Susanna Franzoso; Marina Fanin; Corrado Angelini; Romeo Betto; Dorianna Sandonà
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

5.  Does delta-sarcoglycan-associated autosomal-dominant cardiomyopathy exist?

Authors:  Ralf Bauer; Judith Hudson; Harald D Müller; Clemens Sommer; Gabriele Dekomien; John Bourke; Daniel Routledge; Kate Bushby; Jörg Klepper; Volker Straub
Journal:  Eur J Hum Genet       Date:  2009-03-04       Impact factor: 4.246

6.  Myoclonus dystonia and muscular dystrophy: ɛ-sarcoglycan is part of the dystrophin-associated protein complex in brain.

Authors:  Adrian J Waite; Francesca A Carlisle; Yiumo Michael Chan; Derek J Blake
Journal:  Mov Disord       Date:  2016-08-18       Impact factor: 10.338

7.  Sarcoglycan complex: implications for metabolic defects in muscular dystrophies.

Authors:  Séverine Groh; Haihong Zong; Matthew M Goddeeris; Connie S Lebakken; David Venzke; Jeffrey E Pessin; Kevin P Campbell
Journal:  J Biol Chem       Date:  2009-06-03       Impact factor: 5.157

Review 8.  Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects.

Authors:  Dorianna Sandonà; Romeo Betto
Journal:  Expert Rev Mol Med       Date:  2009-09-28       Impact factor: 5.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.